Bioxyne sees sharp revenue growth as shares jump after strong quarter by Steve Jones October 17, 2024February 25, 2025 Bioxyne chief executive Sam Watson has heralded the “remarkable” progress of the company after a strong […]
Bioxyne forecasts doubling of revenue amid ‘$100m gummy opportunity’ by Steve Jones September 26, 2024September 26, 2024
Montu named as customer behind ‘$28m’ gummy deal as Bioxyne resumes trading on ASX by Steve Jones September 18, 2024September 19, 2024
Financial results: Rua Bioscience; Elixinol Wellness; Argent Biopharma; Wellnex Life; InhaleRx; Bioxyne by Martin Lane and Steve Jones September 2, 2024September 3, 2024
Company news: Rua Bioscience; Avecho; Bioxyne/BLS; iX Biopharma; Ecofibre; Zelira by Steve Jones and Martin Lane August 28, 2024January 13, 2025
Company news: Avecho; Bioxyne; Elixinol Wellness; IDT Australia; Melodiol Global Health; Zelira by Steve Jones July 31, 2024November 25, 2024
Company news: Ecofibre; Bioxyne/BLS; Aurora Cannabis by Steve Jones and Martin Lane May 14, 2024July 16, 2024
Financial results: Bioxyne; Melodiol Global Health; Emyria; Zelira; Elixinol; Wellnex Life; Argent BioPharma by Steve Jones May 1, 2024May 1, 2024
Company news: Bioxyne/BLS; Rua Bioscience; Botanix; Melodiol Global Health; Zelira; Argent BioPharma by Martin Lane and Steve Jones April 16, 2024July 16, 2024
